This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
LJH) has multiple pharmacological effects. Objective To investigate the potential mechanism of LJH in the treatment of myocardial ischemia-reperfusion injury (MIRI) using network pharmacology, molecular docking technology, and in vitro experiments. Background Leonurus japonicus Houtt.
A variety of technologies, including network pharmacology, RNA-sequencing, immunohistochemistry, and Western blotting were performed to investigate its underlying mechanisms.
Recent advances in immune-based therapies, including chimeric antigen receptor (CAR)-T and CAR-macrophage (CAR-M) technologies, have demonstrated potential in impacting on cardiac fibrosis and thus improving surrogate endpoints in preclinical studies.
The study will compare the safety and efficacy of the Laminar LAAX System to commercially available left atrial appendage (LAA) closure devices, providing a potential non-pharmacologic alternative for eligible patients. It's exciting to be part of the evolution of the latest technology into a tangible solution for treating patients.
Left atrial appendage (LAAC) is frequently employed as a non-pharmacological option for thromboembolic prevention in patients with atrial fibrillation (AF). With contemporary device technology, LAAC has proven to be a safe procedure. However, it is important to be vigilant for unusual complications.
Patient administration of aspirin or (and) clopidogrel inhibited platelet adhesion and aggregation on the glass surface under flow conditions. Patient administration of aspirin or (and) clopidogrel inhibited platelet adhesion and aggregation on the glass surface under flow conditions.
Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis. Natural compound libraries were screened to identify potent METTL4 antagonists.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Alun Hughes, professor of Cardiovascular Physiology and Pharmacology at London’s UCL, said Google’s approach sounded credible because of the “long history of looking at the retina to predict cardiovascular risk.” It is only slightly lower than the commonly used blood test method, which has an accuracy rate of 72%.
The study, “Comprehensive Cardiovascular Risk Factor Control with a Mobile Health Cardiovascular Risk Self-Management Program,” highlights the potential use of digital health technology in the comprehensive control of risk factors for cardiovascular disease (CVD), the leading cause of death and disability in the United States. were female.
This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design.
Then, we collected literature-validated TMYXP blood component targets for further network pharmacology analysis.ResultsAll blood components of TMYXP exhibited non-toxic properties. This study focused on peripheral blood mononuclear cell samples from 6 elderly patients with CHD over 60 years old (GSE142008).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content